Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Ned Tijdschr Geneeskd ; 160: D394, 2016.
Artigo em Holandês | MEDLINE | ID: mdl-27758720

RESUMO

BACKGROUND: Autoimmune encephalitis is a rare condition characterized by subacute development of cognitive and psychiatric symptoms. A paraneoplastic syndrome involves autoimmune encephalitis caused by classic antibodies. Although this condition is often associated with cancer, no malignancy has yet been found in 70-90% of patients at the time of diagnosis. CASE DESCRIPTION: We saw a 58-year-old male patient with fatigue, diarrhoea and weight loss. He was also experiencing hyperekplexia, personality changes and an instable gait. PET-CT revealed generalised lymphadenopathy. Histopathological analysis of a lymph node showed mantle cell lymphoma. Further investigation of the fluid revealed anti-DPPX IgG antibodies. We treated the patient's mantle cell lymphoma with R-CHOP; he achieved complete remission and his neurological symptoms resolved almost completely. CONCLUSION: The presence of anti-DPPX IgG antibodies is rare. Although it has not been proven that these antibodies are related to malignancies, this is the third of 30 known cases in which anti-DPPX IgG antibodies and a lymphatic malignancy were found.


Assuntos
Autoanticorpos/análise , Dipeptidil Peptidases e Tripeptidil Peptidases/análise , Encefalite/diagnóstico , Encefalite/tratamento farmacológico , Doença de Hashimoto/diagnóstico , Doença de Hashimoto/tratamento farmacológico , Linfoma de Célula do Manto/diagnóstico , Proteínas do Tecido Nervoso/análise , Canais de Potássio/análise , Anticorpos Monoclonais Murinos , Protocolos de Quimioterapia Combinada Antineoplásica , Ciclofosfamida , Doxorrubicina , Humanos , Linfonodos/química , Linfoma de Célula do Manto/complicações , Linfoma de Célula do Manto/tratamento farmacológico , Masculino , Pessoa de Meia-Idade , Prednisona , Rituximab , Vincristina
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA